MétaCan
Menu
Back to cohort
Record W4407212974 · doi:10.26685/urncst.681

Endometrial Cancer

2025· article· en· W4407212974 on OpenAlexaff
Sofia A. Ierullo

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicEndometrial and Cervical Cancer Treatments
Canadian institutionsWestern University
Fundersnot available
KeywordsEndometrial cancerCancerMedicineGynecologyInternal medicine

Abstract

fetched live from OpenAlex

Introduction and Definition: Endometrial carcinoma, also referred to as endometrial cancer (EC), is a malignant tumor that arises from the epithelial lining of the uterus, known as the endometrium. EC is the most prevalent cancer of the female genital tract in developed countries, and its growing incidence driven by various risk factors is emerging as a significant public health concern. EC’s precise etiology is uncertain, although known risk factors are correlated with estrogen-progesterone imbalances. Due to high morbidity and mortality associated with EC, reviewing recent research on its etiology, risk factors, and future directions is critical. Body: ECs are classified as estrogen-dependent (type I) or estrogen independent otherwise (type II). Type 1 ECs are low-grade, endometrioid tumours often detected early and associated with better prognoses. Type II ECs exhibit non-endometroid histology, including carcinosarcomas, serous carcinomas, clear cell carcinomas, and other molecularly distinct tumours. Classification systems are evolving with new research to incorporate molecular, histological, and clinical factors, enhancing diagnosis and treatment protocols. Major risk factors and treatments emphasize the critical role of estrogen signalling, such that estrogen receptor α (ER) acts as an oncogenic signal. Genomic and nongenomic estrogen signalling pathways both contribute to the development of EC. Type I and type II ECs exhibit distinct risk factors, although both are associated with estrogen-progesterone imbalances. Type I EC risk factors include diabetes, obesity, early-onset menarche, and late-onset menopause, all of which result in prolonged exposure to unopposed estrogen. Type II ECs are less understood, but specific mutations involving TP53, and BRCA1/2 genes are implicated in its risk. The standard approach is often primary debulking surgery (PDS); however, neoadjuvant chemotherapy (NACT) is explored if the disease is deemed surgically unresectable. Ongoing clinical trials are exploring optimal treatment strategies. Germline mutations in the Breast Cancer gene 1/2 (BRCA1/2) are suggested to increase EC risk, although further studies are required to determine if EC is a BRCA1/2-associated disease. Current research suggests BRCA1/2, specifically BRCA1 mutation carriers have increased risk for EC, particularly in those with serous-like histology and TP53 mutations. Specified research can permit targeted treatments from a genetic and oncologic perspective.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.045
Threshold uncertainty score0.152

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.001
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0010.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0450.026

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.487
Teacher spread0.402 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) JournalSame topicEndometrial and Cervical Cancer TreatmentsFrench-language works237,207